{"preliminary_commentary":{"by_channel":{"youtube":2,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"BoB","nct_id":"NCT03767075","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bob-nct03767075. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"BoB","arms":[{"description":"Genomically selected populations will all receive the same drug\n\n* Arm 1A: BRCA1 or BRCA2 mutations\n* Arm 1B: MLH1, MSH2, MSH6, or PMS2 mutations\n* Arm 1C: tumors with POLE mutation, POLD1 mutation\n* Arm 1D: hypermutated tumors\n* Arm 1E: tumors with other mutations in DNA-repair genes\n* Arm 1F: tumors with amplified PDL1\n* Arm 1G: tumours with CDK12 mutations\n\nSubjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1000 subjects will need to be screened in part A in order to enroll 120 patients in part B of module 1.","label":"Module 1 - Atezolizumab","type":"EXPERIMENTAL"},{"description":"Genomically selected populations will all receive the same drug\n\n* Arm 2A: Known pathogenic FGFR1-3 mutations\n* Arm 2B: Variants of unknown significance in FGFR1-3 with functional relevance or pathogenic FGFR4 mutations.\n* Arm 2C: Highly amplified FGFR1-3 with high FGFR1-3 mRNA (with the exception of gastric and breast cancer)\n* Arm 2D: Highly amplifiedFGFR1-3 without high FGFR1-3 mRNA (with the exception of gastric and breast cancer)\n\nSubjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 2000 subjects will need to be screened in part A in order to enroll 80 patients in part B of module 2.","label":"Module 2 - Futibatinib","type":"EXPERIMENTAL"},{"description":"Genomically selected populations will all receive the same drug\n\n* Arm 3A: kinase domain mutations/ MET fusion-genes (including intragene exon skipping MET-MET fusions)\n* Arm 3B: MET copy number gain (equivalent CNG ≥6) (exception: colorectal cancer)\n* Arm 3C: EGFR mutations (exception: primary lung malignancies)\n\nSubjects will be recruited and allocated to arms according to their biomarker profile. It is assumed that 1725 subjects will need to be screened in part A in order to enroll 69 patients in part B of module 3.","label":"Module 3 - Amivantamab","type":"EXPERIMENTAL"}],"collaborators":["Roche Pharma AG","IQVIA Pty Ltd","Taisho Pharmaceutical Co., Ltd.","Janssen, LP"],"completion_date":{"date":"2026-11","type":"ESTIMATED"},"conditions":["Advanced Solid Tumor"],"enrollment":{"count":1000,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Futibatinib","otherNames":["TAS-120"],"type":"DRUG"},{"name":"Amivantamab","otherNames":["JNJ-372"],"type":"DRUG"}],"last_update":"2024-04-25","lead_sponsor":"Vall d'Hebron Institute of Oncology","official_title":"Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumours","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall response rate","timeFrame":"From the first dose date of study treatment to first CR or PR, whichever came earlier, up to 12 weeks (Module 1 & 3) and 16 weeks (Module 2)"}],"references":[],"start_date":{"date":"2018-12-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)","url":"https://clinicaltrials.gov/study/NCT03767075"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bob-nct03767075"}